In addition, in ID8-Vegf peritoneal dissemination mouse model, GM-CSF levels in the tumour ascites were higher in the anti-VEGF antibody-treated group (Fig. 3d), indicating that anti-VEGF therapy enhances GM-CSF levels in the tumour microenvironment. The gene discussed is VEGFA; the disease is neoplasm.